Show simple item record

dc.contributor.authorDean, Emma Jen
dc.contributor.authorWard, Timothy Hen
dc.contributor.authorPinilla, Cen
dc.contributor.authorHoughten, Ren
dc.contributor.authorWelsh, Ken
dc.contributor.authorMakin, Guy W Jen
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorDive, Carolineen
dc.date.accessioned2009-12-09T15:39:50Z
dc.date.available2009-12-09T15:39:50Z
dc.date.issued2009-11-10
dc.identifier.citationA small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. 2009: Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid19904270
dc.identifier.doi10.1038/sj.bjc.6605418
dc.identifier.urihttp://hdl.handle.net/10541/87700
dc.description.abstractBackground:Evasion of apoptosis contributes to the pathogenesis of solid tumours including non-small cell lung cancer (NSCLC). Malignant cells resist apoptosis through over-expression of inhibitor of apoptosis proteins (IAPs), such as X-linked IAP (XIAP).Methods:A phenylurea-based small molecule inhibitor of XIAP, XIAP antagonist compound (XAC) 1396-11, was investigated preclincally to determine its ability to sensitise to clinically relevant cytotoxics, potentially allowing dose reduction while maintaining therapeutic efficacy.Results:XIAP protein expression was detected in six NSCLC cell lines examined. The cytotoxicity of XAC 1396-11 against cultured NSCLC cell lines in vitro was concentration- and time-dependent in both short-term and clonogenic assays. XAC 1396-11-induced apoptosis was confirmed by PARP cleavage and characteristic nuclear morphology. XAC 1396-11 synergised with vinorelbine+/-cisplatin in H460 and A549 NSCLC cells. The mechanism of synergy was enhanced apoptosis, shown by increased cleavage of caspase-3 and PARP and by the reversal of synergy by a pan-caspase inhibitor. Synergy between XAC 1396-11 and vinorelbine was augmented by optimising drug scheduling with superior effects when XAC 1396-11 was administered before vinorelbine.Conclusion:These preclinical data suggest that XIAP inhibition in combination with vinorelbine holds potential as a therapeutic strategy in NSCLC.British Journal of Cancer advance online publication, 10 November 2009; doi:10.1038/sj.bjc.6605418 www.bjcancer.com.
dc.languageENG
dc.language.isoenen
dc.subjectXIAP Antagonist Compounden
dc.subjectXIAPen
dc.subjectApoptosisen
dc.subjectNon-Small-Cell Lung Canceren
dc.titleA small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, England, UK [2] Derek Crowther Unit, Christie Hospital NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, England, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractBackground:Evasion of apoptosis contributes to the pathogenesis of solid tumours including non-small cell lung cancer (NSCLC). Malignant cells resist apoptosis through over-expression of inhibitor of apoptosis proteins (IAPs), such as X-linked IAP (XIAP).Methods:A phenylurea-based small molecule inhibitor of XIAP, XIAP antagonist compound (XAC) 1396-11, was investigated preclincally to determine its ability to sensitise to clinically relevant cytotoxics, potentially allowing dose reduction while maintaining therapeutic efficacy.Results:XIAP protein expression was detected in six NSCLC cell lines examined. The cytotoxicity of XAC 1396-11 against cultured NSCLC cell lines in vitro was concentration- and time-dependent in both short-term and clonogenic assays. XAC 1396-11-induced apoptosis was confirmed by PARP cleavage and characteristic nuclear morphology. XAC 1396-11 synergised with vinorelbine+/-cisplatin in H460 and A549 NSCLC cells. The mechanism of synergy was enhanced apoptosis, shown by increased cleavage of caspase-3 and PARP and by the reversal of synergy by a pan-caspase inhibitor. Synergy between XAC 1396-11 and vinorelbine was augmented by optimising drug scheduling with superior effects when XAC 1396-11 was administered before vinorelbine.Conclusion:These preclinical data suggest that XIAP inhibition in combination with vinorelbine holds potential as a therapeutic strategy in NSCLC.British Journal of Cancer advance online publication, 10 November 2009; doi:10.1038/sj.bjc.6605418 www.bjcancer.com.


This item appears in the following Collection(s)

Show simple item record